VTE Prophylaxis for Laparoscopic Surgery Guidelines: An Update

This statement was reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) on Mar 2017.


William S. Richardson, MD:  Ochsner Medical Center, 1514 Jefferson Hwy # 7N, Jefferson, LA 70121, wrichardson@ochsner.org
Giselle G. Hamad, MD:  Magee-Womens Hospital of UPMC
Dimitrios Stefanidis, MD, PhD:  Indiana University Health North Hospital

Since the publication of the SAGES guidelines for venous thromboembolism (VTE) prophylaxis during laparoscopic surgery in 2007 (1), the American College of Chest Physicians (ACCP) has published their comprehensive guidelines that address VTE prophylaxis for non-orthopedic surgery patients (2). After careful review, the SAGES guidelines committee has approved the endorsement of the ACCP guidelines rather than update our previous VTE guidelines.

The ACCP guidelines utilize the VTE risk stratification systems by Rogers (3) and Caprini (4) and outline prophylaxis strategies based on the calculated risk of VTE. For very low risk patients, ambulation without chemoprophylaxis or mechanical prophylaxis is recommended.  For low risk patients, mechanical prophylaxis with intermittent pneumatic compression (IPC) is advised.  For patients at moderate risk for VTE, the guidelines suggest low molecular weight heparin (LMWH), unfractionated heparin (UH), or mechanical prevention with IPC.  For high risk patients, the ACCP guidelines recommend LMWH or UH plus elastic stockings or IPC.

The 2012 ACCP guidelines are easy to use, are more comprehensive, and are based on stronger evidence than the 2007 SAGES VTE prevention guidelines.  However, they are not specifically directed at laparoscopic surgery patients.  There are differences in VTE risk between open procedures compared with those performed laparoscopically.  In a study comparing the incidence of VTE following laparoscopic versus open surgery in 138,595 patients, there was a statistically significant reduction in risk of VTE after laparoscopic surgery compared to open surgery (5).  The specific type of procedure is not considered in the calculation of VTE risk.

A meta-analysis on laparoscopic cholecystectomy indicated that routine use of VTE chemoprophylaxis was likely to be unnecessary and suggested considering its use only in higher risk patients based on risk stratification (6).  The overall incidence of clinically evident deep venous thrombosis (DVT) was 1.6% without prophylaxis.  Two randomized studies included in that analysis reported on the risk of major bleeding; one reported no major bleeding, while the other study reported major bleeding in 2% in the heparin group versus 3% in the group without chemoprophylaxis. Using the ACCP guidelines, many patients from this study may have been at low to moderate risk using either of the scoring systems and would be given no prophylaxis for a Caprini score of 0, IPC for a score of 1-2, or UH, LMWH, or IPC for a score of 3-4 (moderate risk).  Based on the meta-analysis, there was no significant benefit of chemoprophylaxis in cholecystectomy patients.

Among patients undergoing colon surgery with or without cancer, there is a reduction in VTE using a combination of IPC and chemoprophylaxis.   Data from the Michigan Collaborative of 3,464 patients on dual therapy showed a 1.7% risk of VTE with laparoscopic left vs. 0.5% for right colectomy (7). In this study, older patients, those with higher body mass index (BMI), and patients with angina and postoperative infection had an increased risk of VTE.  With either IPC or chemoprophylaxis alone (single therapy), the risk of VTE was almost twice the risk of using both therapies.  They found no difference in VTE risk with UH vs. LMWH.  An increased risk of bleeding was not observed. In general, these patients fell in the moderate to high risk Caprini group and dual therapy would have been appropriate.   The optimal duration of thromboprophylaxis was studied in a randomized trial of 225 patients undergoing laparoscopic colectomy for cancer.  The incidence of VTE with one week of heparin prophylaxis was 9.7 vs. 0% of patients who received 4 weeks.  The authors concluded that prolonged use of chemoprophylaxis is safe and reduces the risk of VTE compared to using 1 week of heparin (8) .  These recommendations are aligned with the ACCP guidelines, but the small number of patients in this single study limits our ability to support extended chemoprophylaxis strongly.

VTE is a challenging problem after bariatric surgery but there are few randomized controlled trials studying thromboprophylaxis in this population. Most bariatric surgery patients carry multiple risk factors for VTE and therefore are at least at moderate risk for VTE postoperatively.  Despite the elevated VTE risk, the incidence of postoperative VTE is low. A meta-analysis of 19 studies with 3991 patients demonstrated a weighted mean incidence of PE of 0.5% with fixed-dose chemoprophylaxis and an incidence of symptomatic VTE of 0.6% with weight-based chemoprophylaxis (9).  The risk of VTE is lower for laparoscopic compared with open bariatric surgery patients (0.34% versus 1.54%) (10).  Based on the ACCP guidelines, LMWH, unfractionated heparin, or mechanical prophylaxis with IPC are recommended (2).  There is no consensus on the standard of care for chemoprophylactic agent, dosing, timing, or duration.  Dosing of pharmacologic prophylaxis is challenging in postsurgical bariatric surgery patients because dosing by body weight may lead to excessive anticoagulation and bleeding.  Some studies utilize anti-factor Xa levels to determine adequacy of anticoagulation, but therapeutic levels do not necessarily predict a reduction in VTE.  The ACCP guidelines recommend consulting with a pharmacist to determine dosing in obese patients (2).

Prophylactic removable inferior vena cava (IVC) filter use had previously been recommended in high risk bariatric patients such as those with BMI >60, severe pulmonary hypertension, or previous VTE (11).  More recent data argues against the use of prophylactic IVC filter placement.  In 322 of 97,218 patients who received IVC filters and had either gastric bypass or gastric band, there was an increased risk of DVT, length of hospital stay and mortality compared to the non-IVC group (12).  In this study, there was no benefit for prophylactic insertion of IVC filters.  A meta-analysis of prophylactic IVC filters in bariatric surgery demonstrated an increase in the risk of DVT by 3-fold while the increase in mortality was not statistically significant (13).  Long-term complications associated with IVC filters are concerning (14) and most filters are never retrieved (15).  There is insufficient data from randomized studies to support the use of prophylactic IVC filters.

All general surgical patients should be assessed for risk of VTE because of the potential for fatal consequences.  Our endorsement of the ACCP guidelines comes with several caveats.  First, there are very few prospective randomized trials available in the literature addressing VTE prophylaxis in minimally invasive surgery.  The specific type of laparoscopic procedure is not represented in the two VTE risk stratification systems used in the ACCP guidelines.  Bleeding resulting from anticoagulation should be considered when administering and dosing chemoprophylaxis in the postoperative patient.  The optimal agent, dosing, duration, and timing of pharmacologic prophylaxis have not yet been determined.  An individual patient’s specific risk factors for VTE, other medical comorbidities, and the type of procedure must be taken into consideration in cases in which the guidelines do not provide specific recommendations.


Dr. William Richardson has nothing to disclose.   Dr. Giselle Hamad has nothing to disclose.  Dr. Stefanidis reports personal fees from WL Gore and Davol.


  1. Society of American Gastrointestinal & Endoscopic Surgeons Guidelines Committee. Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. Surg Endosc. 2007;21(6):1007-9.
  2. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S-77S.
  3. Rogers SO, Jr., Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg. 2007;204(6):1211-21.
  4. Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199(1 Suppl):S3-10.
  5. Nguyen NT, Hinojosa MW, Fayad C, Varela E, Konyalian V, Stamos MJ, et al. Laparoscopic surgery is associated with a lower incidence of venous thromboembolism compared with open surgery. Ann Surg. 2007;246(6):1021-7.
  6. Rondelli F, Manina G, Agnelli G, Becattini C. Venous thromboembolism after laparoscopic cholecystectomy: clinical burden and prevention. Surg Endosc. 2013;27(6):1860-4.
  7. Henke PK, Arya S, Pannucci C, Kubus J, Hendren S, Engelsbe M, et al. Procedure-specific venous thromboembolism prophylaxis: a paradigm from colectomy surgery. Surgery. 2012;152(4):528-34; discussion 34-6.
  8. Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259(4):665-9.
  9. Becattini C, Agnelli G, Manina G, Noya G, Rondelli F. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2012;8(1):108-15.
  10. Winegar DA, Sherif B, Pate V, DeMaria EJ. Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2011;7(2):181-8.
  11. Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obesity surgery. 2003;13(6):819-25.
  12. Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, D’Ayala M. Concurrent prophylactic placement of inferior vena cava filter in gastric bypass and adjustable banding operations in the Bariatric Outcomes Longitudinal Database. J Vasc Surg. 2012;55(6):1690-5.
  13. Kaw R, Pasupuleti V, Wayne Overby D, Deshpande A, Coleman CI, Ioannidis JP, et al. Inferior vena cava filters and postoperative outcomes in patients undergoing bariatric surgery: a meta-analysis. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2014;10(4):725-33.
  14. Nicholson W, Nicholson WJ, Tolerico P, Taylor B, Solomon S, Schryver T, et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med. 2010;170(20):1827-31.
  15. Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma. 2007;62(1):17-24; discussion -5.

This document was prepared and revised by William S. Richardson, MD, Giselle G. Hamad, MD, Dimitrios Stefanidis, MD, and the SAGES Guidelines Committee

This statement was reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) on Mar 2017.

This is a revision of SAGES publication #16 printed Oct 1992, revised Jan 2006 and Mar 2017.

For more information please contact:

11300 West Olympic Blvd., Suite 600
Los Angeles, CA 90064
(310) 437-0544
(310) 437-0585

Guidelines for clinical practice are intended to indicate preferable approaches to medical problems as established by experts in the field. These recommendations will be based on existing data or a consensus of expert opinion when little or no data are available. Guidelines are applicable to all physicians who address the clinical problem(s) without regard to specialty training or interests, and are intended to indicate the preferable, but not necessarily the only acceptable approaches due to the complexity of the healthcare environment. Guidelines are intended to be flexible. Given the wide range of specifics in any health care problem, the surgeon must always choose the course best suited to the individual patient and the variables in existence at the moment of decision.

Guidelines are developed under the auspices of the Society of American Gastrointestinal and Endoscopic Surgeons and its various committees, and approved by the Board of Governors. Each clinical practice guideline has been systematically researched, reviewed and revised by the guidelines committee, and reviewed by an appropriate multidisciplinary team. The recommendations are therefore considered valid at the time of its production based on the data available. Each guideline is scheduled for periodic review to allow incorporation of pertinent new developments in medical research knowledge, and practice.